JP7716396B2 - 前立腺癌を治療する方法 - Google Patents

前立腺癌を治療する方法

Info

Publication number
JP7716396B2
JP7716396B2 JP2022523564A JP2022523564A JP7716396B2 JP 7716396 B2 JP7716396 B2 JP 7716396B2 JP 2022523564 A JP2022523564 A JP 2022523564A JP 2022523564 A JP2022523564 A JP 2022523564A JP 7716396 B2 JP7716396 B2 JP 7716396B2
Authority
JP
Japan
Prior art keywords
compound
formula
effective amount
pharmaceutical composition
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022523564A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022553954A (ja
JP2022553954A5 (https=
Inventor
アンドリュー ピー． クルー
ザ サード ロイヤル ジェイ． ハスケル
マルシア ドーガン ムーア
ローレンス ビー． スナイダー
ジン ワン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arvinas Operations Inc
Original Assignee
Arvinas Operations Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arvinas Operations Inc filed Critical Arvinas Operations Inc
Publication of JP2022553954A publication Critical patent/JP2022553954A/ja
Publication of JP2022553954A5 publication Critical patent/JP2022553954A5/ja
Priority to JP2025120941A priority Critical patent/JP2025157436A/ja
Application granted granted Critical
Publication of JP7716396B2 publication Critical patent/JP7716396B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022523564A 2019-10-22 2020-10-21 前立腺癌を治療する方法 Active JP7716396B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025120941A JP2025157436A (ja) 2019-10-22 2025-07-18 前立腺癌を治療する方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962924655P 2019-10-22 2019-10-22
US62/924,655 2019-10-22
US201962945418P 2019-12-09 2019-12-09
US62/945,418 2019-12-09
US202063028843P 2020-05-22 2020-05-22
US63/028,843 2020-05-22
US202063032453P 2020-05-29 2020-05-29
US63/032,453 2020-05-29
PCT/US2020/056684 WO2021081108A1 (en) 2019-10-22 2020-10-21 Methods of treating prostate cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025120941A Division JP2025157436A (ja) 2019-10-22 2025-07-18 前立腺癌を治療する方法

Publications (3)

Publication Number Publication Date
JP2022553954A JP2022553954A (ja) 2022-12-27
JP2022553954A5 JP2022553954A5 (https=) 2023-10-20
JP7716396B2 true JP7716396B2 (ja) 2025-07-31

Family

ID=73449188

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022523564A Active JP7716396B2 (ja) 2019-10-22 2020-10-21 前立腺癌を治療する方法
JP2025120941A Pending JP2025157436A (ja) 2019-10-22 2025-07-18 前立腺癌を治療する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025120941A Pending JP2025157436A (ja) 2019-10-22 2025-07-18 前立腺癌を治療する方法

Country Status (10)

Country Link
US (2) US20210113557A1 (https=)
EP (1) EP4048236A1 (https=)
JP (2) JP7716396B2 (https=)
KR (1) KR20220087482A (https=)
CN (1) CN115135313A (https=)
AU (1) AU2020370150A1 (https=)
CA (1) CA3158411A1 (https=)
IL (1) IL292359A (https=)
MX (1) MX2022004808A (https=)
WO (1) WO2021081108A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023547084A (ja) * 2020-10-21 2023-11-09 アルビナス・オペレーションズ・インコーポレイテッド アンドロゲン受容体タンパク質の標的分解のための化合物および方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
CN110506039A (zh) 2016-10-11 2019-11-26 阿尔维纳斯股份有限公司 用于雄激素受体靶向降解的化合物和方法
CR20220630A (es) 2020-05-09 2023-01-23 Arvinas Operations Inc Métodos para fabricar un compuesto bifuncional, formas ultrapuras del compuesto bifuncional y formas de dosificación que comprenden el mismo
WO2022048605A1 (zh) * 2020-09-04 2022-03-10 南昌奥瑞药业有限公司 一种杂环化合物、其制备方法、中间体、组合物以及应用
JP2023552818A (ja) * 2020-12-11 2023-12-19 アルビナス・オペレーションズ・インコーポレイテッド 前立腺癌を治療する方法
CN113620931B (zh) * 2021-09-13 2023-06-09 中国海洋大学 一种雄激素受体抑制剂及其用途
US20250248999A1 (en) * 2022-04-21 2025-08-07 Arvinas Operations, Inc. Bavdegalutamide and combinations thereof for use in treating prostate cancer
WO2024233696A1 (en) * 2023-05-09 2024-11-14 Arvinas Operations, Inc. Bavdegalutamide for treating prostate cancer without ar l702h mutation
TW202535392A (zh) 2023-12-08 2025-09-16 美商亞文納營運公司 使用雄性素受體降解劑治療脊髓延髓性肌肉萎縮

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016511265A (ja) 2013-03-07 2016-04-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新生物の治療のための併用療法
JP2016514707A (ja) 2013-03-15 2016-05-23 アイシューティカ インク．Ｉｃｅｕｔｉｃａ Ｉｎｃ． アビラテロン酢酸エステル製剤
JP2017513862A (ja) 2014-04-14 2017-06-01 アルビナス インコーポレイテッド イミド系タンパク質分解モジュレーター及び関連する使用方法
WO2018064470A1 (en) 2016-09-30 2018-04-05 Janssen Pharmaceutica Nv Methods of diagnosing and treating abiraterone acetate- glucocorticoid -resistant or -sensitive metastatic castration resistant prostate cancer
WO2018071606A1 (en) 2016-10-11 2018-04-19 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
JP2019522644A (ja) 2016-06-10 2019-08-15 ユニバーシティ オブ テネシー リサーチ ファウンデーション 選択的アンドロゲン受容体分解剤（ｓａｒｄ）リガンドおよびその使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
WO2015114314A1 (en) * 2014-01-28 2015-08-06 Cipla Limited Pharmaceutical composition comprising abiraterone
WO2016081472A1 (en) * 2014-11-21 2016-05-26 Biohaven Pharmaceutical Holding Company Ltd. Sublingual formulation of riluzole

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016511265A (ja) 2013-03-07 2016-04-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新生物の治療のための併用療法
JP2016514707A (ja) 2013-03-15 2016-05-23 アイシューティカ インク．Ｉｃｅｕｔｉｃａ Ｉｎｃ． アビラテロン酢酸エステル製剤
JP2017513862A (ja) 2014-04-14 2017-06-01 アルビナス インコーポレイテッド イミド系タンパク質分解モジュレーター及び関連する使用方法
JP2019522644A (ja) 2016-06-10 2019-08-15 ユニバーシティ オブ テネシー リサーチ ファウンデーション 選択的アンドロゲン受容体分解剤（ｓａｒｄ）リガンドおよびその使用方法
WO2018064470A1 (en) 2016-09-30 2018-04-05 Janssen Pharmaceutica Nv Methods of diagnosing and treating abiraterone acetate- glucocorticoid -resistant or -sensitive metastatic castration resistant prostate cancer
WO2018071606A1 (en) 2016-10-11 2018-04-19 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023547084A (ja) * 2020-10-21 2023-11-09 アルビナス・オペレーションズ・インコーポレイテッド アンドロゲン受容体タンパク質の標的分解のための化合物および方法

Also Published As

Publication number Publication date
JP2022553954A (ja) 2022-12-27
US20230128132A1 (en) 2023-04-27
CN115135313A (zh) 2022-09-30
AU2020370150A1 (en) 2022-05-12
US20210113557A1 (en) 2021-04-22
JP2025157436A (ja) 2025-10-15
CA3158411A1 (en) 2021-04-29
WO2021081108A1 (en) 2021-04-29
EP4048236A1 (en) 2022-08-31
IL292359A (en) 2022-06-01
KR20220087482A (ko) 2022-06-24
MX2022004808A (es) 2022-06-08

Similar Documents

Publication Publication Date Title
JP7716396B2 (ja) 前立腺癌を治療する方法
US20240066032A1 (en) Methods of treating prostate cancer
US20210353621A1 (en) Methods of treating prostate cancer
JP2025094174A (ja) エストロゲン受容体分解物質としてのテトラヒドロナフタレン誘導体を用いて乳癌を治療する方法
ES2623503T3 (es) Composiciones para tratar náuseas y vómitos mediados centralmente
ES2910528T3 (es) Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil)piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia
EP3791897A1 (en) Hsp90 inhibitor drug conjugates
US20250248999A1 (en) Bavdegalutamide and combinations thereof for use in treating prostate cancer
TW202011965A (zh) 嗜中性球彈性蛋白酶抑制劑在肝病中之用途
JP6175054B2 (ja) ヒストンアセチルトランスフェラーゼ活性剤の使用
KR20090067210A (ko) 페닐알킬 카바메이트 조성물
EP4734996A1 (en) Compounds and methods for the targeted degradation of androgen receptor
JP2019512475A (ja) 治療に有効な量のジカルボン酸化合物を使用した、病気の予防、治療及び治癒
CN116761607A (zh) 治疗前列腺癌的方法
JP2020536089A (ja) アセトアミノフェン−プレガバリン組み合わせ及び疼痛を処置する方法
WO2024220926A1 (en) Use of an androgen receptor degrader protac for the treatment of prostate cancer
WO2020053658A2 (en) Non-aqueous chemotherapeutic solutions for oral dosage
JP2025527573A (ja) Ｃｄｋ９阻害剤の吸入可能な組成物
JP2005060311A (ja) Ｎ−（ベンゾイル）アミノ酸誘導体を有効成分とするニューロパシー性疼痛治療剤
BR122025008185A2 (pt) Usos terapêuticos de compostos de bifenil sulfonamida para a fabricação de um medicamento para tratar doenças ou transtornos renais em um indivíduo

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231012

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231012

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240911

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241003

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250328

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250624

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250718

R150 Certificate of patent or registration of utility model

Ref document number: 7716396

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150